US2022098229A1PendingUtilityA1
Crystal forms of beta-nicotinamide mononucleotide
Individually held — no corporate assignee on recordPriority: Oct 2, 2015Filed: Jun 9, 2021Published: Mar 31, 2022
Est. expiryOct 2, 2035(~9.2 yrs left)· nominal 20-yr term from priority
C07H 19/048C07H 1/00C07B 2200/13A61P 43/00A61K 31/706A61K 31/7052
75
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to crystalline forms of a β-nicotinamide mononucleotide, methods of their preparation, and related pharmaceutical preparations thereof. The invention also relates to preparations suitable for nutraceutical, veterinary, and agriculturally-relevant uses.
Claims
exact text as granted — not AI-modified1 - 28 . (canceled)
29 . A solid composition comprising a compound having the structure of formula (I),
or a salt thereof, and further comprising one or more solid orally-acceptable excipients or carriers, wherein said composition is in a unit dosage form for human administration of 0.01 to 3000 mg, and further wherein said composition is formulated as a dietary supplement.
30 . The solid composition of claim 29 , wherein said composition is pyrogen-free.
31 . The solid composition of claim 29 , wherein said composition is non-pyrogenic.
32 . The solid composition of claim 29 , wherein said unit dosage form is a pill.
33 . The solid composition of claim 29 , wherein said unit dosage form is a tablet.
34 . The solid composition of claim 29 , wherein said unit dosage form is a capsule.
35 . The solid composition of claim 34 , wherein said capsule is a gelatin capsule.
36 . The solid composition of claim 29 , wherein said one or more solid orally-acceptable excipients or carriers comprise gelatin.
37 . The solid composition of claim 29 , wherein said one or more solid orally-acceptable excipients or carriers comprise hydroxypropylmethyl cellulose.
38 . The solid composition of claim 29 , wherein said one or more solid orally-acceptable excipients or carriers comprise sodium carboxymethyl cellulose.
39 . A method of preparing a dietary supplement comprising combining (i) a compound having the structure of formula (I),
or a salt thereof, with (ii) one or more solid orally-acceptable excipients or carriers, to form a solid composition,
wherein said composition is in a unit dosage form for human administration of 0.01 to 3000 mg, and further wherein said composition is formulated as a dietary supplement.
40 . The method of claim 39 , wherein said composition is pyrogen-free.
41 . The method of claim 39 , wherein said composition is non-pyrogenic.
42 . The method of claim 39 , wherein said unit dosage form is a pill.
43 . The method of claim 39 , wherein said unit dosage form is a tablet.
44 . The method of claim 39 , wherein said unit dosage form is a capsule.
45 . The method of claim 39 , wherein said one or more solid orally-acceptable excipients or carriers comprise gelatin.
46 . The method of claim 39 , wherein said one or more solid orally-acceptable excipients or carriers comprise hydroxypropylmethyl cellulose.
47 . The method of claim 39 , wherein said one or more solid orally-acceptable excipients or carriers comprise sodium carboxymethyl cellulose.
48 . A method of supplementing a diet comprising providing a composition to a human for self-administration, wherein the composition is a solid composition comprising a compound having the structure of formula (I),
or a salt thereof, and further comprising one or more solid orally-acceptable excipients or carriers, wherein said composition is in a unit dosage form for human administration of 0.01 to 3000 mg, and further wherein said composition is formulated as a dietary supplement.Join the waitlist — get patent alerts
Track US2022098229A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.